On November 30, 2022, the Board appointed Alexander (Bo) Cumbo as Solid Biosciences Inc.'s President and Chief Executive Officer and elected Mr. Cumbo as a member of the Board, in each case, subject to and contingent and effective upon the closing of the Acquisition (the “Effective Date”). As previously disclosed, the Company entered into an employment agreement with Mr. Cumbo on September 29, 2022, effective as of the Effective Date. Mr. Cumbo, age 51, has served as the President and Chief Executive Officer and as a director of AavantiBio since October 2020.

From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences Inc., a biopharmaceutical company.

Mr. Cumbo has served on the board of Verve Therapeutics Inc. since June 2022. Mr. Cumbo previously served on the board of RA Pharmaceuticals Inc. Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University. On November 30, 2022, the Board also elected Adam Koppel, M.D., Ph.D., as a member of the Board, subject to and contingent and effective upon the closing of the Acquisition.

Dr. Koppel previously served as a member of the Board from October 2017 to June 2022. Mr. Cumbo and Dr. Koppel will serve as a Class I and Class II directors, respectively, with a term expiring at the Company's 2025 and 2023 annual meeting of stockholders, respectively, and thereafter until such director's successor has been duly elected and qualified or until such director's earlier death, resignation or removal. Other than as contemplated in the Merger Agreement, there are no arrangements or understandings between Mr. Cumbo or Dr. Koppel and any other persons pursuant to which Mr. Cumbo or Dr. Koppel, respectively, was elected as a director.